Skip to main content
Premium Trial:

Request an Annual Quote

Affy and Qiagen Pen Collaboration on GeneChips, siRNA

NEW YORK, Oct. 31 (GenomeWeb News) - Affymetrix and Venlo, Netherlands-based Qiagen announced today that they have agreed to collaborate by using Affy's GeneChip to optimize Qiagen's siRNA technology.


The companies said that access to Affy's arrays would allow Qiagen to determine the on- and off-target effects of siRNA's silencing effect on a genome-wide scale.


"The whole-genome view that Affymetrix arrays offer will give researchers a more complete understanding of the downstream effects of siRNAs in their experiments and clinical research," Trevor Nicholls, Affy's chief commercial officer, said in a statement.


Financial terms of the agreement were not disclosed.


The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.